bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2010: M F J
2009: D N O S A J J M A M

 
  Other news for:
Neoplasms
Acquired Immunodeficiency Syndrome
Sexually Transmitted Diseases
 Resources from HONselect
HIV Patients More Prone to 7 Kinds of Cancer
Study found early treatment of infection could slow start of malignancies

By Robert Preidt

WEDNESDAY, Oct. 7 (HealthDay News) -- The weakened immune systems of people with HIV puts them at increased risk for at least seven types of cancer, but early diagnosis and treatment of HIV infection could help delay the onset of some of these cancers, a new study suggests.

French researchers examined the incidence of three AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin's lymphoma and cervical cancer) and four non-AIDS-defining cancers (Hodgkin's lymphoma, lung cancer, liver cancer and anal cancer) in 52,278 HIV-infected people.

The study authors also analyzed the association between immunodeficiency, viral load, antiretroviral treatment and the onset of the seven cancers. Overall, immunodeficiency increased the risk of all the cancers, and CD4 cell count was the most predictive risk factor for all the cancers except anal cancer. The cancer risk associated with viral load was lower than that associated with immunodeficiency, the researchers noted.

CD4 count was the only risk factor for Hodgkin's lymphoma, lung cancer and liver cancer, the study found. Increased risk of Kaposi's sarcoma and non-Hodgkin's lymphoma was associated with lower CD4 count, higher HIV viral load and a lack of combination antiretroviral therapy (cART).

A higher CD4 count was associated with a lower risk of cervical cancer, and patients taking cART were half as likely to develop cervical cancer. Anal cancer risk increased with the time during which CD4 count was less than 200 cells per microliter and viral load was greater than 100,000 copies per milliliter, according to the report.

The study appears online Oct. 7 in advance of publication in the November print issue of The Lancet Oncology.

"Our results suggest that cART would be most beneficial if it restores or maintains the CD4 count above 500 cells per microliter, thereby indicating an earlier diagnosis of HIV infection and earlier treatment initiation," the researchers wrote.

The study authors called for effective cancer-specific screening programs for HIV patients and said all HIV-positive women should be regularly offered cervical cancer screening.

More information

The American Cancer Society has more about AIDS-related cancers.

SOURCE: The Lancet Oncology, news release, Oct. 7, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved. URL:http://www.healthscout.com/template.asp?id=631730

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Risk
CD4 Lymphocyte Count
Viral Load
Therapeutics
Lymphoma
Anus Neoplasms
Infection
Cells
Research Personnel
Liver
Diagnosis
Mass Screening
HIV Infections
Risk Factors
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact